advertisement
Wolf AT 12
Showing records 1 to 12 | Display all abstracts from Wolf AT98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf AT
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Shin JD
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf AT
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Wolf AT; Wolf AT
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Harris A; Oddone F
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Harris A
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Siesky B
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Verticchio Vercellin A; Siesky B
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Verticchio Vercellin A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Rowe LW; Rowe LW
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Ciulla TA
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Packles M; Oddone F
Acta Ophthalmologica 2022; 100: e377-e385
